Your Search for 'Insomnia Therapeutics - Pipeline Assessment and Market Forecasts to 2018' returned 2 results - Page 1 of 1

• Pipeline and Commercial Insight: Insomnia - Future of Innovative Orexin Drug Class in Doubt

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Jul 2010 , Pages: 257
  insomnia epidemiology in Brazil and China. - Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and country-specific sales forecasts to 2019. Highlights ...

• Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GlobalData, Nov 2011 , Pages: 87
  Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the ...